352 related articles for article (PubMed ID: 19671042)
1. The VHL tumor suppressor: master regulator of HIF.
Haase VH
Curr Pharm Des; 2009; 15(33):3895-903. PubMed ID: 19671042
[TBL] [Abstract][Full Text] [Related]
2. The VHL tumor suppressor and HIF: insights from genetic studies in mice.
Kapitsinou PP; Haase VH
Cell Death Differ; 2008 Apr; 15(4):650-9. PubMed ID: 18219317
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
Miller F; Kentsis A; Osman R; Pan ZQ
J Biol Chem; 2005 Mar; 280(9):7985-96. PubMed ID: 15611064
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
Cockman ME; Masson N; Mole DR; Jaakkola P; Chang GW; Clifford SC; Maher ER; Pugh CW; Ratcliffe PJ; Maxwell PH
J Biol Chem; 2000 Aug; 275(33):25733-41. PubMed ID: 10823831
[TBL] [Abstract][Full Text] [Related]
5. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
Knauth K; Cartwright E; Freund S; Bycroft M; Buchberger A
J Biol Chem; 2009 Apr; 284(16):10514-22. PubMed ID: 19228690
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
Jung YS; Lee SJ; Yoon MH; Ha NC; Park BJ
Cell Cycle; 2012 Dec; 11(23):4462-73. PubMed ID: 23159849
[TBL] [Abstract][Full Text] [Related]
7. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
9. The HIF and other quandaries in VHL disease.
Tarade D; Ohh M
Oncogene; 2018 Jan; 37(2):139-147. PubMed ID: 28925400
[TBL] [Abstract][Full Text] [Related]
10. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
11. Parallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α.
Okumura F; Uematsu K; Byrne SD; Hirano M; Joo-Okumura A; Nishikimi A; Shuin T; Fukui Y; Nakatsukasa K; Kamura T
Mol Cell Biol; 2016 Jun; 36(12):1803-17. PubMed ID: 27090638
[TBL] [Abstract][Full Text] [Related]
12. Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer.
Chakraborty AA
Semin Cancer Biol; 2020 Dec; 67(Pt 2):34-42. PubMed ID: 32209418
[TBL] [Abstract][Full Text] [Related]
13. USP9X destabilizes pVHL and promotes cell proliferation.
Zhang C; Peng Z; Zhu M; Wang P; Du X; Li X; Liu Y; Jin Y; McNutt MA; Yin Y
Oncotarget; 2016 Sep; 7(37):60519-60534. PubMed ID: 27517496
[TBL] [Abstract][Full Text] [Related]
14. The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting.
Haase VH
Semin Cell Dev Biol; 2005; 16(4-5):564-74. PubMed ID: 15908240
[TBL] [Abstract][Full Text] [Related]
15. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
16. The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease.
Haase VH
Kidney Int; 2006 Apr; 69(8):1302-7. PubMed ID: 16531988
[TBL] [Abstract][Full Text] [Related]
17. WSB1 promotes tumor metastasis by inducing pVHL degradation.
Kim JJ; Lee SB; Jang J; Yi SY; Kim SH; Han SA; Lee JM; Tong SY; Vincelette ND; Gao B; Yin P; Evans D; Choi DW; Qin B; Liu T; Zhang H; Deng M; Jen J; Zhang J; Wang L; Lou Z
Genes Dev; 2015 Nov; 29(21):2244-57. PubMed ID: 26545811
[TBL] [Abstract][Full Text] [Related]
18. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis.
Pugh CW; Ratcliffe PJ
Semin Cancer Biol; 2003 Feb; 13(1):83-9. PubMed ID: 12507560
[TBL] [Abstract][Full Text] [Related]
19. Effects of point mutations in pVHL on the binding of HIF-1α.
Domene C; Illingworth CJ
Proteins; 2012 Mar; 80(3):733-46. PubMed ID: 22105711
[TBL] [Abstract][Full Text] [Related]
20. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]